CD4 and influenza: In a recent study evaluating safety and humoral immunogenicity through 6 months after mRNA-1010 vaccination, as well as antigenic breadth against A/H3N2 viruses and cellular immunogenicity, mRNA-1010 vaccine induced robust CD4+ T-cell responses, with higher frequencies of influenza strain-specific polyfunctional CD4+ T cells observed at Days 8 and 29 compared with placebo (33).